Selective blockade of estrogen receptor beta improves wound healing in diabetes

Endocrine. 2014 Jun;46(2):347-50. doi: 10.1007/s12020-013-0144-3. Epub 2013 Dec 24.

Authors

Vivekananda Gupta Sunkari¹, Ileana R Botusan, Octavian Savu, Jacob Grünler, Xiaowei Zheng, Jan-Åke Gustafsson, Kerstin Brismar, Sergiu-Bogdan Catrina

Affiliation

¹ Department of Molecular Medicine and Surgery, Karolinska Institutet, Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska University Hospital Solna, L1:01, 17176, Stockholm, Sweden.

PMID: 24366647
DOI: 10.1007/s12020-013-0144-3

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cell Line
Diabetes Mellitus, Experimental / complications*
Diabetic Foot / drug therapy*
Diabetic Foot / genetics
Diabetic Foot / metabolism
Estrogen Receptor Antagonists / pharmacology*
Estrogen Receptor Antagonists / therapeutic use
Estrogen Receptor alpha / antagonists & inhibitors
Estrogen Receptor alpha / genetics
Estrogen Receptor alpha / metabolism
Estrogen Receptor beta / antagonists & inhibitors*
Estrogen Receptor beta / genetics
Estrogen Receptor beta / metabolism
Humans
Mice, Knockout
Piperidines / pharmacology
Piperidines / therapeutic use
Pyrazoles / pharmacology
Pyrazoles / therapeutic use
Pyrimidines / pharmacology
Pyrimidines / therapeutic use
Wound Healing / drug effects*
Wound Healing / physiology

Substances

1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol
Estrogen Receptor Antagonists
Estrogen Receptor alpha
Estrogen Receptor beta
Piperidines
Pyrazoles
Pyrimidines